The summer doldrums are over. Biotech news came at a breakneck pace this week both before and after Labor Day, starting with the surprise resignation of Novartis’s top executive just days after the Swiss company notched an historic FDA approval.
From... Read more »
[Updated 4:26 p.m. See below.] Amazon sent cities across North America into a frenzy Thursday after announcing plans to build a second headquarters outside of Seattle, bringing with it tens of thousands of jobs and billions of dollars in... Read more »
Biotech CEOs Jeremy Levin and Steve Holtzman are continuing their recent push to spur the life sciences industry to speak out against government policies it doesn’t agree with.
Levin, CEO of Ovid Therapeutics (NASDAQ: OVID) and Holtzman, the head of... Read more »
A top prize in American biomedical science was awarded today to two scientists for their discoveries that led to the development of a human papillomavirus (HPV) vaccine, which prevents cervical cancer caused by the sexually transmitted virus.
Douglas Lowy (pictured right),... Read more »
Shelly Sahi, founder and CEO of Sahi Cosmetics, thought she wanted to be a doctor. It wasn’t until she finished her undergraduate studies at the University of Michigan that she realized how burnt out she was—and that a career in... Read more »
The University of Michigan’s Life Sciences Institute (LSI) is hosting its 16th annual Saltiel Life Sciences Symposium later this month, and for the first time, rather than focusing on a narrow segment of the industry, the lineup of speakers... Read more »
[Corrected 9/5/17, 12:22 p.m. See below.] The far-out idea of reprogramming a patient’s immune cells to fight cancer, known as CAR-T, entered the mainstream this week, and two numbers highlight the tale. The first is $11.9 billion, the price... Read more »
Novartis said Wednesday that it would not charge for its newly approved cellular immunotherapy, tisagenlecleucel (Kymriah)—the first so-called CAR-T product to ever come to market—if it fails to help patients within a month. If the cell therapy, approved for kids with... Read more »
When Neurable first popped up on Xconomy’s radar in late 2015, it was a small, mostly student-led University of Michigan spinout working on cutting-edge brain-computer interface innovations that would allow people to control software using only their thoughts. Back then, it... Read more »